Twelve-months Extension Study to Explore the Long-Term Safety and Efficacy of Subcutaneous Administration of GV1001 1.12 Mg/day in Patients with Progressive Supranuclear Palsy Who Completed Study GV1001-PSP-CL2-011

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 25 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tertomotide (Primary)
Indications Progressive supranuclear palsy
Focus Adverse reactions
Sponsors GemVax & KAEL

Most Recent Events

23 Oct 2024 Planned End Date changed from 30 Jul 2025 to 1 Dec 2025.
23 Oct 2024 Planned primary completion date changed from 15 Dec 2024 to 1 Nov 2025.
23 Oct 2024 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight